ReviewThe American journal of psychiatry2026

Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.

Shih-Hsuan Ku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.